Emma L. Burrows

Dr. Emma L. Burrows

orcid

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2015 in Molecular Autism
Verified
Journal Article
Open access
PDF file
EBEmma L. Burrows
Emma L. Burrows
LLLiliana Laskaris
Liliana Laskaris
LKLynn Koyama
Lynn Koyama
LCLeonid Churilov
Leonid Churilov
JBJoel Bornstein
Joel Bornstein
AHAnthony J. Hannan
Anthony J. Hannan
Aggression is common in patients with autism spectrum disorders (ASD) along with the core symptoms of impairments in social communication and repetitive behavior. Risperidone, an atypical antipsychotic, is widely used to treat aggression in ASD. In order to understand the neurobiological underpinnings of these challenging behaviors, a thorough characterisation of behavioral endophenotypes in animal models is required. We investigated aggression in mice containing the ASD-associated R451C (arginine to cysteine residue 451 substitution) mutation in neuroligin-3 (NL3). Furthermore, we sought to verify social interaction impairments and assess olfaction, anxiety, and repetitive and restrictive behavior in NL3R451C mutant mice. We show a pronounced elevation in aggressive behavior in NL3R451C mutant mice. Treatment with risperidone reduced this aggression to wild-type (WT) levels. Juvenile and adult social interactions were also investigated, and subtle differences in initiation of interaction were seen in juvenile NL3R451C mice. No genotype differences in olfactory discrimination or anxiety were observed indicating that aggression was not dependent on altered olfaction, stress response, or social preference. We also describe repetitive behavior in NL3R451C mice as assessed by a clinically relevant object exploration task. The presence of aberrant aggression and other behavioral phenotypes in NL3R451C mice consistent with clinical traits strengthen face validity of this model of ASD. Furthermore, we demonstrate predictive validity in this model through the reversal of the aggressive phenotype with risperidone. This is the first demonstration that risperidone can ameliorate aggression in an animal model of ASD and will inform mechanistic and therapeutic research into the neurobiology underlying abnormal behaviors in ASD.

10 February 2015 in Neuropsychopharmacology
Verified
Journal Article
Closed access
EBEmma L. Burrows
Emma L. Burrows
CMCaitlin E McOmish
Caitlin E McOmish
LBLaetitia S Buret
Laetitia S Buret
MBMaarten Van Den Buuse
Maarten Van Den Buuse
AHAnthony J Hannan
Anthony J Hannan



1 August 2011 in Progress in Neuro-Psychopharmacology and Biological Psychiatry
Verified
Journal Article
Closed access
EBEmma L. Burrows
Emma L. Burrows
CMCaitlin E. McOmish
Caitlin E. McOmish
AHAnthony J. Hannan
Anthony J. Hannan

1 October 2015 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
GCGursharan Chana
Gursharan Chana
LLLiliana Laskaris
Liliana Laskaris
CPChristos Pantelis
Christos Pantelis
PGPiers Gillett
Piers Gillett
RTRenee Testa
Renee Testa
ESEfstratios Skafidas
Efstratios Skafidas